Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study

Richi, Patricia; Martín, María Dolores; Navío, María Teresa; Gonzalez‐Hombrado, Laura; Salido, Marina; Llorente, Jesús; Thuissard-Vasallo, I.J.; Alcocer, P.; Saa-Requejo, Carmen; Jiménez-Diaz, Ana; Cebrián, Laura; Lojo, L.; García-Castro, Marta; Sanz-Rosa, D.; Castro, Patricia; Fernández‐Rodríguez, Sandra; Aramayona, María José Martínez de; Steiner, Martina; Cobo, T.; García-Fernández, Cristina; Fernández‐Castro, Mónica; Illera, Óscar; Valverde, R.

doi:10.1016/j.medcle.2019.02.031

Cited by 3 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, reduced immune response to influenza vaccination as measured by increases in antibody titers was demonstrated in patients with psoriatic arthritis or ankylosing spondylitis treated with rituximab but not in those treated with methotrexate, anti‐tumor necrosis factor (anti‐TNF) therapy, or biologics 67 . A study in autoimmune patients on anti‐TNF agents also confirmed no reduced immune response to influenza vaccination 18 …”

Section: Therapeutic Immunosuppressants Used For Autoimmune Diseasesmentioning

confidence: 93%

“…A small study of seven patients with Non‐Hodgkin's Lymphoma (NHL) treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab (R‐CHOP) demonstrated that influenza vaccination produced a humoral response to recall antigens but not the primary antigen 16 . Other studies have found decreased rates of seroconversion after influenza vaccination among patients treated with rituximab compared with healthy controls or patients treated with other immunosuppressants, such tumor necrosis factor (TNF) inhibitors, or non‐immunosuppressive therapies, such as disease‐modifying antirheumatic drugs (DMARDs) 17‐20 . Additionally, several studies found reduced immune response following influenza vaccine administration in rituximab‐treated patients with rheumatoid arthritis (RA) 21‐25 ; however, one study showed that the immune response to influenza vaccine seemed to return 6 to 10 months following rituximab administration 24 .…”

Section: Rituximabmentioning

confidence: 99%

“…67 A study in autoimmune patients on anti-TNF agents also confirmed no reduced immune response to influenza vaccination. 18 Several studies in patients with autoimmune diseases failed to show reduced immune response to influenza vaccination in patients on immunosuppressive therapy with corticosteroids and/ or DMARDs, TNF inhibitors, or IL-6 receptor antagonists compared with either healthy controls or patients not on immunotherapy. [68][69][70] For patients with autoimmune diseases on immunosuppressant therapy, the ability of influenza vaccination to induce an immune response depends on the type of drug therapy used for treatment.…”

Section: Influenza Vaccinesmentioning

confidence: 99%

“… 16 Other studies have found decreased rates of seroconversion after influenza vaccination among patients treated with rituximab compared with healthy controls or patients treated with other immunosuppressants, such tumor necrosis factor (TNF) inhibitors, or non‐immunosuppressive therapies, such as disease‐modifying antirheumatic drugs (DMARDs). 17 , 18 , 19 , 20 Additionally, several studies found reduced immune response following influenza vaccine administration in rituximab‐treated patients with rheumatoid arthritis (RA) 21 , 22 , 23 , 24 , 25 ; however, one study showed that the immune response to influenza vaccine seemed to return 6 to 10 months following rituximab administration. 24 Similar results were seen in rituximab‐treated patients following influenza vaccination in other disease states including neuromyelitis optica spectrum disorder, other rheumatologic conditions, and NHL.…”

Section: Rituximabmentioning

confidence: 99%

“… 67 A study in autoimmune patients on anti‐TNF agents also confirmed no reduced immune response to influenza vaccination. 18 …”

Section: Therapeutic Immunosuppressants Used For Autoimmune Diseasesmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Bemben

Berg

2022

Pharmacotherapy

View full text Add to dashboard Cite

Inactivated vaccines are generally considered safe in immunocompromised patients but the ability of immunocompromised patients to generate an effective immune response to vaccines is uncertain. Although recent reviews have focused on the effects of vaccines in patients who are immunocompromised due to various disease states (primary immunodeficiency), the effects of immunosuppressive drug therapy (secondary immunodeficiency) has received relatively less attention. This review evaluates evidence regarding the efficacy of inactivated vaccines against influenza, COVID-19, and other diseases in patients treated with immunosuppressive oncologic agents, immunosuppressants used for transplant recipients, and immunosuppressants used for autoimmune disorders. Although evidence is mixed for many immunosuppressive agents and vaccines, most studies have found an attenuated immune response to inactivated vaccines, with the majority of data indicate anti-B-cell antibodies have a more severe and prolonged negative effect on vaccine efficacy. K E Y W O R D S antirheumatic agents, immunosuppressive agents, inactivated vaccine, vaccine | 335 BEMBEN aNd BERG over 10 kg], as defined by the Advisory Committee on Immunization Practices [ACIP]), were considered to be immunosuppressive agents. 4 How to cite this article: Bemben NM, Berg ML. Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy. Pharmacotherapy.

show abstract

Section: Therapeutic Immunosuppressants Used For Autoimmune Diseasesmentioning

confidence: 93%

Section: Rituximabmentioning

confidence: 99%

Section: Influenza Vaccinesmentioning

confidence: 99%

Section: Rituximabmentioning

confidence: 99%

“… 67 A study in autoimmune patients on anti‐TNF agents also confirmed no reduced immune response to influenza vaccination. 18 …”

Section: Therapeutic Immunosuppressants Used For Autoimmune Diseasesmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Bemben

Berg

2022

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Vaccination in Rheumatology: New Data (Based on Recommendations of the European League Against Rheumatism)

Белов

Тарасова

Muravyova

2020

jour

View full text Add to dashboard Cite

Comorbid infections have a significant effect on morbidity and mortality in modern rheumatology, especially in immune-mediated inflammatory rheumatic diseases (IMIRD). In this regard, vaccination is becoming increasingly important in the prevention of infections in IMIRD. The article analyzes an updated version of the recommendations for vaccination of adult patients with IMIRD, proposed by experts of the European League Against Rheumatism at the end of 2019. The safety and immunogenicity of vaccination associated with the prevention of various infections in patients with IMIRD are discussed. The main directions of future research on this issue are outlined.

show abstract

One year in review 2020: novelties in the treatment of rheumatoid arthritis

Silvagni

Sakellariou

Bortoluzzi

et al. 2020

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients' preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.

show abstract

Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study

Cited by 3 publications

References 23 publications

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy

Vaccination in Rheumatology: New Data (Based on Recommendations of the European League Against Rheumatism)

One year in review 2020: novelties in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About